Background: Why is RSV More Severe in Infants?
During the COVID-19 pandemic, physicians observed that infants hospitalized with respiratory syncytial virus (RSV) infection often had more severe symptoms than those hospitalized with SARS-CoV-2, despite both being respiratory RNA viruses.
Key Findings: Divergent Immune Responses
To understand these differences, scientists from St. Jude Children's Research Hospital and The Jackson Laboratory (JAX) compared the immune responses of infants infected with either virus at a single-cell level. The study revealed:
- RSV Infection: Was linked to unexpectedly low levels of systemic inflammation and a poorly coordinated early immune response, primarily by natural killer cells. It also appeared to reprogram parts of the infant immune system at the epigenetic level.
- SARS-CoV-2 Infection: Showed a hyperinflammatory immune response profile.
"We showed, for the first time, that two similar respiratory viruses, RSV and SARS-CoV-2, cause very different types of immune dysregulation in young infants," said co-corresponding author Octavio Ramilo, MD.
Implications and Future Directions
Published in Science Translational Medicine, this study not only explains the potential mechanisms behind the clinical differences but also underscores the need for different treatment strategies for distinct viruses. Understanding these immune response variations is crucial for developing more precise interventions and therapies to protect infants from severe respiratory infections.